De-escalating Surgery Among Patients with HER2+and Triple Negative Breast Cancer

被引：2

作者：

Tasoulis, Marios-Konstantinos ^{[1
,2
]}

Heil, Joerg ^{[3
]}

Kuerer, Henry M. ^{[4
]}

机构：

[1] Royal Marsden NHS Fdn Trust, Breast Surg Unit, Fulham Rd, London SW3 6JJ, England

[2] Inst Canc Res, Div Breast Canc Res, Old Brompton Rd, London SW7 3RP, England

[3] Heidelberg Univ Hosp, Univ Breast Unit, Dept Obstet & Gynecol, Heidelberg, Germany

[4] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA

来源：

CURRENT BREAST CANCER REPORTS | 2022年 / 14卷 / 04期

关键词：

Surgical de-escalation; Breast surgery; Triple negative; HER2; positive; Breast cancer; PATHOLOGICAL COMPLETE RESPONSE; SENTINEL NODE BIOPSY; 20-YEAR FOLLOW-UP; NEOADJUVANT CHEMOTHERAPY; RADICAL-MASTECTOMY; MULTICENTER; TRIAL; IDENTIFICATION; AXILLA; IMPACT;

D O I：

10.1007/s12609-022-00453-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of Review De-escalation of surgery has been central in the evolution of multidisciplinary management of breast cancer. Advances in oncology and increasing use of neoadjuvant chemotherapy (NACT) have opened opportunities for further surgical de-escalation especially for HER2 + and triple negative (TN) disease. The aim of this review is to discuss the recent data on de-escalation of surgery as well as the future directions. Recent Findings Patients with TN and HER2 + breast cancer with excellent response to NACT would be the ideal candidates for surgical de-escalation. Post-NACT image-guided biopsy, potentially combined with machine learning algorithms, may accurately identify patients achieving pathologic complete response that would be eligible for clinical trials assessing safety of omission of breast and axillary surgery. Multidisciplinary research is required to further support results of preliminary studies. Current data point towards a future when even less or no surgery may be required for exceptional responders.

引用

页码：135 / 141

页数：7

共 50 条

[21] De-escalating and escalating systemic therapy of early breast cancer
Smith, Ian E.
Okines, Alicia F. C.
BREAST, 2017, 34 : S5 - S9
[22] De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer
Di Leo, A.
Pestrin, M.
Siclari, O.
Sanna, G.
Moretti, E.
Biganzoli, L.
BREAST, 2017, 32 : S21 - S21
[23] DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer
Debien, Veronique
Adam, Virginie
Coart, Elisabeth
Agostinetto, Elisa
Goulioti, Theodora
Molinelli, Chiara
Arahmani, Amal
Zoppoli, Gabriele
Piccart, Martine
FUTURE ONCOLOGY, 2023, 19 (24) : 1655 - 1667
[24] De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer
McCartney, Amelia
Vignoli, Alessia
Hart, Christopher
Tenori, Leonardo
Luchinat, Claudio
Biganzoli, Laura
Di Leo, Angelo
BREAST, 2017, 34 : S13 - S18
[25] Importance of accurate clinical staging in patients with early stage HER2+and triple negative breast cancer.
Sidda, Adarsh
Biglow, Layana Roslyn
Manu, Gurusidda
Abdallah, Mahmoud
Maria, R. B.
Tirona, Tria
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[26] De-Escalating the Management of In Situ and Invasive Breast Cancer
Angarita, Fernando A.
Brumer, Robert
Castelo, Matthew
Esnaola, Nestor F.
Edge, Stephen B.
Takabe, Kazuaki
CANCERS, 2022, 14 (19)
[27] De-escalating and escalating radiation therapy in the management of early breast cancer
Poortmans, P.
BREAST, 2017, 32 : S2 - S3
[28] De-escalating Local Treatment for Women with Breast Cancer
Cheng-Har Yip
Indian Journal of Surgery, 2022, 84 : 611 - 615
[29] De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+and Triple-Negative Breast Cancer
Gonzalez, Lorena
Mortimer, Joanne
Kruper, Laura
CURRENT BREAST CANCER REPORTS, 2021, 13 (03) : 151 - 156
[30] De-escalating Local Treatment for Women with Breast Cancer
Yip, Cheng-Har
INDIAN JOURNAL OF SURGERY, 2022, 84 (SUPPL 3) : 611 - 615

← 1 2 3 4 5 →